Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme.

Literature DB >> 26823616

Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme.

Matthew R Rutledge¹, J Aubrey Waddell¹, Dominic A Solimando¹.

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities: Chemical Disease

Year: 2015 PMID： 26823616 PMCID： PMC4686471 DOI： 10.1310/hpj5008-672

Source DB: PubMed Journal: Hosp Pharm ISSN： 0018-5787

17 in total

Review 1. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Authors: F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr
Journal: Ann Oncol Date: 2010-05 Impact factor: 32.976

2. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544

Review 3. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544

4. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.

Authors: Ashwatha Narayana; Deborah Gruber; Saroj Kunnakkat; John G Golfinos; Erik Parker; Shahzad Raza; David Zagzag; Patricia Eagan; Michael L Gruber
Journal: J Neurosurg Date: 2011-10-28 Impact factor: 5.115

5. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.

Authors: Douglas E Ney; Julie A Carlson; Denise M Damek; Laurie E Gaspar; Brian D Kavanagh; B K Kleinschmidt-DeMasters; Allen E Waziri; Kevin O Lillehei; Krishna Reddy; Changhu Chen
Journal: J Neurooncol Date: 2014-12-19 Impact factor: 4.130

6. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors: Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245

7. A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245

8. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.

Authors: Antonio Omuro; Kathryn Beal; Philip Gutin; Sasan Karimi; Denise D Correa; Thomas J Kaley; Lisa M DeAngelis; Timothy A Chan; Igor T Gavrilovic; Craig Nolan; Adilia Hormigo; Andrew B Lassman; Ingo Mellinghoff; Christian Grommes; Anne S Reiner; Katherine S Panageas; Raymond E Baser; Viviane Tabar; Elena Pentsova; Juan Sanchez; Renata Barradas-Panchal; Jianan Zhang; Geraldine Faivre; Cameron W Brennan; Lauren E Abrey; Jason T Huse
Journal: Clin Cancer Res Date: 2014-08-08 Impact factor: 12.531